TY - JOUR
T1 - Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice
AU - Caocci, Giovanni
AU - Mulas, Olga
AU - Abruzzese, Elisabetta
AU - Iurlo, Alessandra
AU - Annunziata, Mario
AU - Orlandi, Ester Maria
AU - Galimberti, Sara
AU - Binotto, Gianni
AU - Sgherza, Nicola
AU - Luciano, Luigia
AU - Martino, Bruno
AU - Russo Rossi, Antonella
AU - Bonifacio, Massimiliano
AU - Fozza, Claudio
AU - Trawinska, Malgorzata Monika
AU - Cattaneo, Daniele
AU - Elena, Chiara
AU - Baratè, Claudia
AU - De Gregorio, Fiorenza
AU - Molica, Matteo
AU - La Nasa, Giorgio
AU - Foà, Robin
AU - Breccia, Massimo
PY - 2019/1/1
Y1 - 2019/1/1
N2 - There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML patients treated with bosutinib, stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 40-month cumulative incidence of CV-AEs was 25.2 ± 8.1%. Patients with the SCORE of high–very high showed a significantly higher incidence of CV-AEs (55 ± 12.9% vs 9 ± 9.5%; p = 0.002). Overall, 9 CV-AEs were reported, with 2 deaths attributed to CV-AE. In conclusion, the SCORE assessment before starting treatment is helpful in identifying CV-AE high-risk patients during bosutinib treatment.
AB - There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML patients treated with bosutinib, stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 40-month cumulative incidence of CV-AEs was 25.2 ± 8.1%. Patients with the SCORE of high–very high showed a significantly higher incidence of CV-AEs (55 ± 12.9% vs 9 ± 9.5%; p = 0.002). Overall, 9 CV-AEs were reported, with 2 deaths attributed to CV-AE. In conclusion, the SCORE assessment before starting treatment is helpful in identifying CV-AE high-risk patients during bosutinib treatment.
KW - Acetylsalicylic acid
KW - Bosutinib
KW - Cardiovascular risk
KW - Chronic myeloid leukemia
UR - http://www.scopus.com/inward/record.url?scp=85065256448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065256448&partnerID=8YFLogxK
U2 - 10.1007/s00277-019-03705-y
DO - 10.1007/s00277-019-03705-y
M3 - Article
AN - SCOPUS:85065256448
VL - 98
SP - 1885
EP - 1890
JO - Revue d'hématologie
JF - Revue d'hématologie
SN - 0939-5555
IS - 8
ER -